IntelGenx Reports Results for the Nine Months Ended September 30, 2008

November 12, 2008

SAINT LAURENT, QUEBEC,  Nov. 12, 2008 (Marketwire) IntelGenx  Technologies Corp. (TSX:IGX)(OTCBB:IGXT) ("IntelGenx") today announced its results for the nine months ended September 30, 2008.


Successfully completed pivotal clinical trials for CPI-300, which confirm that CPI-300 is bioequivalent to the reference product. CPI-300 was formulated using IntelGenx’s proprietary controlled release technology. It contains a new strength of antidepressant developed to complete the dosing options for physicians who currently prescribe the drug. CPI-300 provides a more convenient dosing option for those patients currently taking the higher strength and is expected to be indicated for the treatment of major depressive disorder (MDD).


The balance of restricted cash available to complete CPI-300 is $724,521 at September 30, 3008 (December 31, 2007: nil), in line with expectations.

Cash and cash equivalents (excluding restricted cash) at September 30, 2008 of $766,012 (December 31, 2007: $330,967). 

Net loss of $839,209 for the three months ended September 30, 2008 (September 30, 2007: $533,480), in line with expectations.

Report 20,850,002 common shares outstanding at September 30, 2008 (December 31, 2007: 16,157,146).

In announcing the results, Horst Zerbe, President and Chief Executive Officer of IntelGenx, said:
“The third quarter marked a significant milestone for IntelGenx with the confirmation that we have attained bioequivalency with the CPI-300 antidepressant. I am pleased to add that this success has been achieved within the budget and in line with the project timetable. We are now preparing the 505(b)(2) NDA and plan to submit the application with the FDA in the first quarter of 2009.”

About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at

Forward Looking Statements:
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

The TSX and OTCBB have neither approved nor disapproved of the information contained herein.

Dr. Horst G. Zerbe, President and CEO
IntelGenx Corp.
(514) 331-7440x201